![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
birdwatcherТелеграммы про гардазил продолжают поступать: Bloomberg -- The analysis by Harvard researchers predicted that life expectancy gained by giving Gardasil to females older than 18 doesn't outweigh the vaccine's expense. The findings may raise qualms for Merck, which recently stepped up marketing to women ages 19 to 26 after Gardasil sales declined 9 percent to $326 million last quarter.[...]
``We aren't saying older women can't benefit. We are just saying that from a societal perspective there might be a better use of this investment in money,'' said Jane Kim, an author on the study and an assistant professor of health decision science at Harvard University. ``You are getting diminishing returns.'' [...]
A treatment is typically considered cost effective if it is less than $50,000 or $100,000 for one additional year of life, Kim said.[...]
``There is good reason to be cautious about introducing large-scale vaccination programs,'' Haug said. ``Instead, we should concentrate on finding more solid answers through research rather than base consequential and costly decisions on yet unproven assumptions.''
``We aren't saying older women can't benefit. We are just saying that from a societal perspective there might be a better use of this investment in money,'' said Jane Kim, an author on the study and an assistant professor of health decision science at Harvard University. ``You are getting diminishing returns.'' [...]
A treatment is typically considered cost effective if it is less than $50,000 or $100,000 for one additional year of life, Kim said.[...]
``There is good reason to be cautious about introducing large-scale vaccination programs,'' Haug said. ``Instead, we should concentrate on finding more solid answers through research rather than base consequential and costly decisions on yet unproven assumptions.''
